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During the past decade great progress has 
been made in the field of organ replacement. 
This has established renal transplantation 
as an accepted method of treatment of 
chronic renal failure and to date more than 
9,000 kidney transplants have been per-
formed throughout the world. Experience 
with replacement of other major organs is 
limited and the procedures are being carried 
out in only a few transplantation centers. 
LIVER TRANSPLANTATION 
Since the first liver transplantation in man 
was performed in Denver in March 1963, 
162 such operations have been performed 
throughout the world. 3 Approximately one-
third of the patients have been treated at 
the University of Colorado Medical Center 
and the Denver Veterans Administration 
Hospital. 
Liver transplantation may consist of an 
orthotopic operation, in which the patient's 
diseased liver is removed and replaced with 
a healthy one, or an auxiliary transplant in 
which the host liver is left undisturbed and 
an extra liver is placed in an ectopic position 
within the abdomen. Theoretically, the lat-
ter procedure is attractive as it retains what-
ever function still remains in the host organ. 
In practice, however, the operation has great 
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drawbacks. There is little room in the abdo-
men for a second liver; it may be technically 
difficult in man to provide blood flow from 
the intestines into the ectopic liver's portal 
system; and from animal studies it appears 
that there may be competition between the 
two livers with the result that the liver which 
fails to receive splanchnic blood (usually 
the auxiliary liver) undergoes atrophy. The 
clinical results with this operation have been 
very disappointing and the procedure will 
not be considered any further. 
Indications and Contraindications. Or-
thotopic replacement of the liver is indi-
cated in patients with serious liver disease 
whose life expectancy is a matter of days or 
weeks or perhaps a few months. The reasons 
for operation in our center are listed in 
Table 1. We have not transplanted the liver 
for metastatic malignancy, as has been at-
tempted in other centers, because of the 
strong likelihood of other, extrahepatic, 
metastases. With the exception of one case 
where the tumor was adherent to the pylorus 
which also required resection, we have not 
performed transplants for primary hepatic 
cancers which have extended beyond the 
confines of the liver. 
The current status of liver transplantation 
can be illustrated by some examples from 
our own clinical material.25- 28 In our early 
experience it was hoped that hepatic re-
placement might be useful therapy for pri-
mary cancers of the liver. However, as long-
term survival was achieved, it became ob-
vious that tumor recurrence was a major 
problem. In 6 of 7 patients treated for can-
cer and followed from 2 to 14 months after 
transplantation, metastases appeared in the 
lungs, the brain and even in the homografts 
(Figs. 1 and 2). 
The sole exception was a child aged al-
most 4 years who was operated upon for 
severe congenital biliary atresia. An inci-
dental finding in the liver specimen was a 









Biliary Atresia 26' 
Primary Hepatic Tumors 13 
Cirrhosis 9 
Chronic Aggressive Hepatilis 6 
Wilson's Disease 2 
Lupoid Hepalitis 1 
Relransplanlation for severe rejeclion 4 
T~al m 
, One patient had an incidental hepatoma. 
tient has now been followed for more than 
2!i; years with no clinical, radiologic or sero-
logic (a-fetoprotein estimations) evidence 
of recurrent tumor. Isolated long-term suc-
cesses have also been achieved by Prof. Roy 
Calne5 of Cambridge and Dr. Pierre Daloze8 
of Montreal. 
These disappointing results have made us 
adopt a policy of restricting liver transplan-
tation almost eXclusively to patients with 
benign hepatic disease. 
Encouraging results have been obtained 
in patients with congenital biliary atresia. 




after transplantation. Three of these sur-
vived more than two years and one lived for 
3-} years. The last recipient had a very poor 
tissue match. Despite this he had two minor 
rejection episodes in the early postoperative 
period. Thereafter, he enjoyed good health 
and excellent liver function until shortly be-
fore his death. A biopsy of the homograft 
914 days after transplantation showed al-
most normal liver architecture. A few 
month later, the patient developed a hemo-
philus type B septicemia which led to circu-
latory collapse, renal failure and massive 
hepatic necrosis that contributed to death a 
few weeks later. 
Our experience with liver transplantation 
has given us a better understanding of Wil-
son's disease . The condition is believed to 
result from an enzyme deficiency which 
causes disturbed copper metabolism and 
leads to extensive copper deposition in the 
liver, basal ganglia, the corneas (Kayser-
Fleischer rings) and other tissues. The main 
clinical manifestations are severe cirrhosis, 
or neurologic disturbances or both. Experi-
ence with liver transplantation suggests that 
the enzyme deficiency may be corrected by 
replacement of the diseased liver with a 
healthy one and that copper metabolism may 
be restored to normal. One such patient, 
aged 11 years, was seriously ill with ad-
vanced cirrhosis. Three weeks after trans-
plantation the homograft underwent one of 
c o 
FIG. 1. Destruction of an hepatic homograft by tumor recurrence, as demonstrated by serial 
technetium liver scans. A. 68 days-The scan appears normal. B. 94 days-The patient had be-
come jaundiced. Hepatomegaly is evident. C. 101 days-Multiple areas of poor isotope concen-
tration are now visible. D. 111 days-The process has continued its rapid progression. By the 
time of death-143 days after transplantation-the homograft was almost completely replaced 
by tumor. (By permission of W.B. Saunders Co., 1969) 
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FIG. 2. Same patient as in Figure 1. Autopsy specimen showing multiple large pulmonary 
metastases. (By permission of W. B. Saunders Co., 1969) 
the worst rejection crises we have ever ob-
served in any of our liver transplant recip-
ients . The bilirubin rose to almost 50 mgm/ 
ml with an associated elevation of the 
alkaline phosphatase. Fortunately, it was 
possible to reverse the immunologic reaction 
and the patient has enjoyed virtually normal 
liver function for the ensuing three years. 
After operation large amounts of copper 
were passed in the urine for six months. 
Biopsies of the homograft at 6, 18 and 30 
months showed a normal copper concen-
tration within the organ. The patient is now 
31; years post-transplantation and is attend-
ing school. Similar good results were ob-
tained in another boy aged 15 years who is 
now 18 months post-transplantation. 
Is there any hope of treating lethal serum 
hepatitis with liver transplantation? In the 
present state of our knowledge it is not pos-
sible to give a definite answer to this ques-
tion. We have no experience with hepatic 
replacement in the treatment of acute ful-
minating hepatitis, although it has been un-
successfully attempted elsewhere. However, 
we have performed liver replacement in 
cases of hepatic failure caused by chronic 
aggressive hepatitis, Australia antigen posi-
tive . The serum of one such patient, a 28 
year old woman, has been persistently posi-
tive for the Australia antigen for two years. 
At the time of admission to the hospital she 
was gravely ill with severe ascites, large 
pleural effusions, a serum albumin of less 
than 2 gm/ l00 ml and a prothrombin time 
of less than 20%. Following transplantation 
her serum promptly became negative for 
the Australia antigen and remained so for 
approximately two months when it again 
became positive. Soon afterwards her liver 
chemistries became abnormal and it was ap-
parent that she again had hepatitis . Despite 
slowly deteriorating liver function she was 
restored to a useful life among her family 
and friends for 20 months, when she died 
of disseminated Nocardia infection. At au-
topsy, there was recurrence of chronic ag-
gressive hepatitis. 
Complications. The most frequent prob-
lems after liver transplantation have been 
with rejection or infection. The former may 
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manifest itself as a cholestatic jaundice with 
hepatomegaly and elevation of the alkaline 
phosphatase. More severe rejection may lead 
to hepatic necrosis with increases in trans am-
inases. Frequently it is possible to reverse 
rejection with increased immunosuppressive 
therapy. However, in some cases this has 
proved impossible and caused the patient's 
death unless another homograft could be ob-
tained and retransplantation performed. 
Infection is common in any patient whose 
immunologic system is impaired by immuno-
suppressive therapy. It is particularly com-
mon in hepatic transplantation as a rejecting 
liver is unable to handle micro-organisms 
reaching it from the bowel. Septic hepatic 
infarcts may occur or even frank septicemia, 
usually with gram negative enteric organ-
isms. 
Long-Term Survival. Long-term survival 
can be achieved after liver transplantation. 
In experiments in dogs and pigs we have had 
many survive more than a year. One dog is 
still alive more than eight years after trans-
plantation. In our first 46 patients, in whom 
a minimum potential follow-up of 12 months 
was or is available, 12 survived at least one 
year (26%). Five of these recipients lived 
more than two years, one of whom died 3t 
years after transplantation. At present nine 
of our patients are alive at It, 4, 5, 5, 7, 14, 
18, 32 and 38 months posttransplantation, 
respectively. Other current long-term sur-
vivors include a patient of Dr. Daloze8 (30 
months) and of Prof. Calne5 (43 months). 
HEART TRANSPLANTATION 
The first cardiac transplant was performed 
in Jackson, Mississippi in 1964, when a 
chimpanzee heart was transplanted to man. 
Three years later the first human to human 
transplantation was attempted. To date 189 
heart transplantations have been performed 
throughout the world.3 
Indications and contraindications. In 
the selection of cardiac transplant recipients 
the patients must have terminal heart dis-
ease not amenable to any other surgical pro-
cedure or medical treatment. Since most 
heart disease is caused by coronary arterio-
sclerosis, this has been the most common 
reason for cardiac transplantation. 7, 22 Myo-
cardiopathy is another indication despite the 
theoretical danger that the immune factors 
responsible for the original disease could 
damage the homograftP Rheumatic multi-
valvular disease, although often correctable 
by valve replacement, may have caused such 
severe damage as to require cardiac trans-
plantation. Severe uncorrectable congenital 
anomalies also may warrant heart replace-
ment. 
Definite contraindications are severe pul-
monary hypertension and, as with other kinds 
of transplants, severe systemic disorders such 
as diabetes, infection or cancer. Most pa-
tients with multiple organ disease should not 
undergo cardiac transplantation, and pa-
tients of advanced age or questionable emo-
tional status are usually not suitable. 
Complications. As with transplantation 
of other organs, the major postoperative 
problems have been rejection and infection. 
Decrease in exercise tolerance is a warning 
of impending acute rejection." 22 Clinical 
findings in the early stages are the appear-
ance or accentuation of a previously present 
pericardial friction rub, and the develop-
ment of an abnormal diastolic heart sound, 
usually an early diastolic gallop, although 
a presystolic gallop may occur. 
The electrocardiogram provides many of 
the primary indices of acute rejection. Char-
acteristic and reversible changes include 
decreased electrocardiographic voltage, atrial 
arrhythmias, rightward deviation of the 
mean electrical axis, and ischemic type ST 
segment changes. Ultrasound cardiography 
shows increased total heart and right ven-
tricular chamber size, thickening of the left 
ventricular wall, and variable decreases in 
the transverse diameter of the left ventricu-
lar cavity.30 Elevations of the enzymes LDH, 
CPK and SGOT do not provide an early 
warning but merely reflect the severity of 
the rejection process. Decreased uptake of 
Caesium 131 chloride by the myocardium 
may also be useful in the diagnosis,17 
Chronic rejection results from intimal 
thickening in the coronary arteries and their 
branches and has been responsible for many 
of the late deaths following cardiac trans-
plantation.' It manifests itself by a progres-
sive reduction in exercise tolerance and the 
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development of cardiac failure. In some 
centers attempts have been made to prevent 
this complication with long-term anticoagu-
lant therapy and the use of the platelet de-
aggregator, dipyridamole.18 Experience with 
this form of treatment is still too small to 
draw any definite conclusions. 
Long-term Survival. As heart failure 
develops medical treatment for this condi-
tion will have to be instituted. Attempts 
have been made to replace chronically re-
jecting hearts with secondary cardiac homo-
grafts, but no long-term survivals have yet 
been obtained.7, 17 
The results of cardiac transplantation 
have been steadily improving. Shumway and 
his colleagues, with the largest experience, 
have performed 45 transplants in 43 pa-
tients. Currently they have a 43 % one-year 
and 37% two-year surviva1.11 
Of the 189 patients treated throughout 
the world 29 are still alive.3 The longest 
survivor is now more than four years post-
transplantation. 
LUNG TRANSPLANTATION 
The first attempted lung transplantation 
in man took place in Jackson, Mississippi 
in 1963. Since then, 29 such procedures 
involving either a lobe, a whole lung or the 
heart and both lungs have been performed.3 
Indications and contraindications. Lung 
transplantation is not indicated in unilateral 
pulmonary disease where a lobectomy or 
pneumonectomy should suffice. The prime 
candidates for this procedure are pa-
tients who are gravely ill with chronic re-
strictive lung disease or conceivably with 
primary pulmonary hypertension. 10, 35 Uni-
lateral transplantation in patients with 
chronic obstructive pulmonary disease has 
failed, largely owing to a serious ventila-
tion/perfusion imbalance between the homo-
graft and the host's residual lung. Attempts 
have been made to overcome this problem 
with bilateral lung replacement. Occasional 
transplants have also been performed for 
acute respiratory insufficiency caused by 
toxic pneumonitis or trauma.35 
Complications. Postoperatively, acute re-
jection is heralded by general malaise, 
cough, dyspnea and a fall of arterial p02 
values. The risk of pulmonary infection is 
particularly great, and a disconcerting fea-
ture is that it is wel~-nigh impossible to dis-
tinguish between this and rejection of the 
homograft. 
Long-Term Survival. Thus far the re-
sults of lung transplantation have been very 
disappointing as most patients have suc-
cumbed within a few weeks. The longest 
survivor, Derom'slO patient in Belgium, died 
of bronchopneumonia and chronic rejection 




The first pancreaticoduodenal transplant 
was performed in Minneapolis in 1966. To 
date, 25 such operations have been per-
formed. H 
Indications and Contraindications. 
Transplantation of the pancreas and duo-
denum (to provide drainage of the exocrine 
secretions of the former organ), or of the 
body and tail of the pancreas alone, is indi-
cated in cases of severe juvenile-onset dia-
betes complicated by marked retinopathy 
and nephropathy. 20, 21 In most cases so far 
treated, the kidney damage has been so 
marked as to necessitate renal replacement 
at the same time as the pancreatic trans-
plantation. As more experience is gained, 
a trend may develop towards replacing the 
pancreas before the stage of terminal 
nephropathy, thus eliminating the need for 
concomitant renal transplantation. In addi-
tion, new techniques will be required which 
will eliminate the need for concomitant 
transplantation of the duodenum. 
Complications. A successful pancreatic 
transplantation is followed by a normal fast-
ing blood sugar and glucose tolerance test. 
Postoperatively, the major problems have 
been with sepsis, often due to duodenal ne-
crosis, and rejection of the kidneys even 
though in each case the renal grafts were 
obtained from the same donors as the pan-
creata. 20. 21 Pancreatic rejection is heralded 
by recurrence of diabetes or elevation of the 
serum amylase or lipase levels.20 . :J2 
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Partial pancreatic transplants have not 
functioned for periods longer than fOUl 
months. Failure was caused by pancreatitis, 
infection, autolysis and/or other technical 
problems associated with the procedure.20• 21 
Survival. The longest survivor following 
pancreatic transplantation succumbed after 
12 months. Currently two patients are alive 
following the procedure.:l 
BONE MARROW 
TRANSPLANTATION 
Several hundred bone marrow transplants 
have been performed to date. Since January 
1, 1968 the AC.S.-N.I.H. Organ Transplant 
Registry has recorded 146 such procedures 
in J 30 recipients. 
Indications and Contraindications. Bone 
marrow transplants are usually performed 
in patients who are seriously ill with one of 
the following disorders4 • 34 which have failed 
to respond to other forms of treatment: 
1) Accidental whole-body irradiation; 2) 
Aplastic anemia; 3) Immune deficiency dis-
eases, including agammaglobulinemia, hypo-
gammaglobulinemia, the Wi scott-Aldrich 
syndrome and the DiGeorge syndrome (the 
aim in these conditions is to either reconsti-
tute all the hemopoietic cells or only those 
belonging to the lymphoid series). 4) Leu-
kemia; 5) A variety of advanced cancers. 
In the last two conditions the aim is not 
only to restore depleted blood elements, but 
to provide immunocompetent cells which, it 
is hoped, will destroy residual malignant 
cells which have persisted despite other 
forms of therapy. 
Preoperative donor workup should ex-
clude the possibility of transmissible infec-
tions or malignant disease. For successful 
bone marrow transplantation, the ideal donor 
is an identical twin, as there is no need for 
immunosuppressive therapy in these cases. 
Otherwise, a relative who is closely matched 
for the ABO, Rh and HL-A antigens should 
be used. The one-way mixed lymphocyte 
culture test seems to be particularly useful 
in selecting well matched combinations. In 
the absence of a familial volunteer, an un-
related donor, either living or cadaveric, 
may be used. However, at present most of 
the worthwhile long-term results have been 
obtained in transplants between HL-A iden-
tical siblings. 
Recipients with leukemia and other types 
of cancer usually require treatment with one 
or more cancer chemotherapeutic agents. 
Before transplantation immunosuppressive 
pretreatment is given using total body irra-
diation, steroids, azathioprine, cyclophos-
phamide or anti-lymphocyte globulin. In 
some centers pretreatment of the donor 
with ALG is being investigated. 24 
Except in transplants between identical 
twins, the recipients often require continua-
tion of immunosuppressive therapy post-
transplantation to prevent rejection of the 
homograft or a graft versus host reaction. 
Frequent hematologic studies are neces-
sary to establish that the grafted bone mar-
row is functioning and that a state of partial 
or complete chimerism has been established. 
Survival of the transfused cells is determined 
by mcans of erythrocyte or leukocyte anti-
genic markers, or both. 
Complications. After transplantation the 
most frequent problems are pcrsistence of 
the original malignant disease, or the devel-
opment of infection or rejection. In cases of 
leukemia the disease may persist or it may 
involve the transplanted donor cells as oc-
curred in two cases reported by Thomas.33 
Infectious problems are prone to occur be-
cause many patients already have impaired 
immune responses which may be further 
reduced by immunosuppressive agents. 
Rejection may be of two types: 4 1) Fail-
ure of engraftment is heralded by a disap-
pearance of the initial symptomatic and 
hematologic improvement. Hemorrhage or 
infection may occur and further bone mar-
row transplants may be necessary; 2) Graft 
versus host disease (G.V.H.D.) is a dis-
order in which immunologically competent 
donor cells become established and react to 
the host's tissues as if they were foreign. 
The resulting immunologic reaction results 
in an illness characterized by generalized 
wasting and malaise, gastrointestinal dys-
function (with anorexia, diarrhea, malab-
sorption and weight loss), exfoliative der-
matitis, destruction of hepatic tissue with 
abnormal liver function tests and jaundice, 
fever and an increased susceptibility to fun-
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gal and viral infections.13 The disorder may 
occur despite HL-A identity,13 suggesting 
that antigenic differences must reside in as 
yet undetected non-HL-A sites. G.V.H.D. 
occurs in two forms: an acute type which 
begins within a few days of transplantation 
and either results in early death of the host 
or regresses, with recovery within 4 to 6 
weeks; and a chronic syndrome which oc-
curs more than 30 days after transfusion.31 
Attempts have been made to prevent or 
minimize G.V.H.D. by using grafts of hemo-
poietic stem cells with as few lymphoid cells 
as possible. 1 Pretreatment of the recipient 
with ALG has also been successfully used 
to prevent G.V.H.D.24 
Survival. At the present time, 43 pa-
tients are alive with functioning bone mar-
row grafts. The longest survivor is 43 months 
post -transplan ta tion. 3 
SPLEEN TRANSPLANTS 
At least eight patients have received 
splenic homografts. The chief indication has 
been in patients with terminal carcinoma in 
whom it was hoped to induce a graft (donor 
spleen) versus host (recipient's carcinoma) 
reaction by providing a continuous source 
of immunocompetent cells which were for-
eign to the host lymphatic system.23 The 
spleen donors had been sensitized with non-
viable tumor cells obtained from biopsy of 
the recipient's cancer. Other splenic trans-
plants have aimed to replace the suspected 
enzyme deficiency in Gaucher's disease;14 to 
correct the immunologic deficiency in a child 
with agammaglobulinemia;23 and to provide 
Factor VIII in a severe case of hemophilia.15 
The results thus far have been disappoint-
ing, with survival of the transplant for only 
a few weeks.9 
THYMUS TRANSPLANTS 
Transplants of fetal thymic tissue have 
been used in an attempt to restore immuno-
logic competence in various syndromes of 
congenital immunologic deficiency. Many of 
these transplants have failed and some pa-
tients have developed graft-versus-host dis-
ease. However, in two cases of the DiGeorge 
syndrome (congenital thymic aplasia) im-
munologic competence has persisted for 16 
and 18 months respectively, with gratifying 
clinical improvement;2, G while a child with 
Swiss-type agammaglobulinemia was mak-
ing good progress almost six months after 
receiving a cadaver fetal thymus plus a bone 
marrow transplant from his sister.9 
LARYNX TRANSPLANTS 
Transplantation of the larynx has been 
performed in one patient who underwent a 
total laryngectomy for carcinoma. He died 
of recurrent cancer 10 months later.19 
SMALL BOWEL TRANSPLANTS 
The first small bowel transplant was done 
in Minneapolis in 1967. Less than 10 cases 
have been performed since then. 
Small bowel transplantation may be indi-
cated in patients with severe malnutrition 
resulting from "the short bowel syndrome" 
caused by removal of most of the small 
bowel for Crohn's disease, mesenteric vas-
cular occlusion, trauma or congenital atresia. 
After transplantation the patient is initially 
maintained mainly by parenteral nutrition 
until the lymphatics of the homograft have 
had an opportunity to link up with those 
of the host-after which full oral feeding 
may be commenced. It is useful to bring 
out a small isolated loop of the homograft 
to the skin surface to provide serial biopsies 
which may provide an indication of impend-
ing rejection. 16 The longest survival to date 




Replacement of organs such as the thyroid 
or the adrenal gland is not necessary, as the 
missing hormones can be readily supplied 
by mouth with no risk to the patient. In our 
own center a parathyroid gland transplant 
has been successfully performed in a patient 
who was already receiving immunosuppres-
sion to prevent rejection of a renal homo-
graft. 
At the present time transplantation of or-
gans such as the testis, ovary, uterus or 
urinary bladder are not justified, because 
the risks of immunosuppressive therapy far 
outweigh any benefits to be gained 'from 
replacement of these organs. 
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FUTURE PROSPECTS 
Most of the techniques of transplantation 
of the extrarenal organs have been fully 
worked out. Much more experience needs 
to be gained with pre- and post-operative 
management of the recipients before these 
procedures can be practiced as extensively 
as kidney transplantation is today. But there 
are grounds for optimism. As mentioned 
previously, the results of cardiac transplan-
tation are steadily improving. Futhermore, 
we should bc able to improve on our 26 % 
one-year survival figures with liver trans-
plantation. We have learned to avoid many 
of the pitfalls encountered in our early ex-
perience. Another reason for hope hinges 
on new developments in immunosuppression. 
Studies in renal homograft recipients during 
the past 18 months have shown that aza-
thioprine can be effectively replaced as an 
immunosuppressive agent by small doses of 
cyclophosphamide, which does not appear 
to be as hepatotoxic. 29 In addition, a poorly 
functioning liver may fail to metabolize aza-
thioprine properly. Cyclophosphamide, on 
the other hand, is given in its metabolically 
active form and should be effective no mat-
ter what the state of hepatic function. In 
our most recent experience using cyclophos-
phamide in combination with prednisone 
and antilymphocyte globulin, 5 of 6 liver 
recipients have done well from 1 t to 7 
months after operation. If these preliminary 
encouraging findings are confirmed by fur-
ther experience, new advances in liver trans-
plantation may become feasible. 
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